490 results match your criteria AIDS reviews[Journal]


COVID-19 Comes 40 Years After AIDS - Any Lesson?

AIDS Rev 2020 05 14;22(2). Epub 2020 May 14.

Laboratory of Internal Medicine, Puerta de Hierro University Hospital, Madrid. Spain.

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit health-care systems and societies in an unprecedented manner. In 1981, the first cases of AIDS were reported and wide diagnostic testing helped to characterize high-risk groups and the global burden of the epidemic. With Coronavirus Disease (COVID)-19, everything has happened too fast and both cases and fatalities are huge but still uncertain in most places. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M20000030DOI Listing

CD8 + T-lymphocyte Encephalitis: A Systematic Review.

AIDS Rev 2020 Feb 12:1-11. Epub 2020 Feb 12.

Department of Neuroradiology, Hospital Universitário Cassiano Antônio de Moraes da Universidade Federal do Espírito Santo - HUCAM/UFES/EBSERH. Vitória, Espírito Santo, Brazil.

The increase of CD8 + T lymphocytes in the perivascular spaces of patients with HIV encephalopathy has been reported in some studies. CD8 + T lymphocyte encephalitis was first described in 2013 and then a few other similar cases were published. We proposed to analyze the clinical, MR imaging, and histopathology findings of CD8 + T lymphocyte encephalitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000132DOI Listing
February 2020

Adherence to HIV Care and Associated Health Functioning among Youth Living with HIV in Sub-Saharan Africa.

AIDS Rev 2020 Feb 13:1-10. Epub 2020 Feb 13.

Department of Psychiatry, Rhode Island Hospital, Providence, Rhode Island.

Older adolescents and young adults (youth) living with HIV (YLH) in sub-Saharan Africa (SSA) are at high risk for poor HIV treatment adherence and associated negative health outcomes including viral nonsuppression. To describe this risk, we conducted a comprehensive review of studies involving YLH. Eligible studies compared youth adherence or adherence-related health functioning to older or younger samples, examined factors associated with adherence or health outcomes among YLH, or evaluated adherence interventions with YLH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000101DOI Listing
February 2020

Pre-exposure Prophylaxis in HIV Research: A Latent Dirichlet Allocation Analysis (GAPRESEARCH).

AIDS Rev 2020 Feb 13:1-9. Epub 2020 Feb 13.

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.

Pre-exposure prophylaxis (PrEP) has been shown to be an effective approach to prevent human immunodeficiency virus (HIV) infections; however, implementation of the service remains challenging. This global bibliometric analysis aims to describe the current trends in HIV research prevention through PrEP to reveal the potential gaps of knowledge and to put forward recommendations for future research. A bibliometric analysis was conducted through Web of Science from 1990 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000131DOI Listing
February 2020
3.787 Impact Factor

Global Mapping of Interventions to Improve the Quality of Life of People Living with HIV/AIDS: Implications for Priority Settings.

AIDS Rev 2020 Feb 12:1-15. Epub 2020 Feb 12.

Department of Psychological Medicine, Yong Loo Lin School of Medicine, Singapore.

Enhancing the quality of life (QOL) of people living with HIV and AIDS (PLWHA) has become a significant global health goal, as combination antiretroviral therapy has helped to transform HIV/AIDS from a fatal illness to chronic disease. In this study, we aim to comprehensively describe the growth of research publications and the development of research landscapes regarding interventions to improve QOL among PLWH, as well as to characterize interdisciplinary topics and emerging interests of the research community. English articles and reviews published from 1991 to 2018 concerning interventions to improve QOL among PLWHA were retrieved from the Web of Science. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000135DOI Listing
February 2020
3.787 Impact Factor

Disseminated Mycobacterium avium on HIV/AIDS: Historical and Current Literature Review.

AIDS Rev 2020 ;22(1):9-15

Instituto de Infectologia Emilio Ribas, Universidade de São Paulo, Brazil.

Combination antiretroviral therapy (cART) has changed Mycobacterium avium epidemiology. A significant decrease in the incidence of disseminated M. avium complex: (DMAC) infection was observed between pre-cART and post-cART periods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000104DOI Listing
January 2020

Impact of New Coronavirus Epidemics on HIV-Infected Patients

AIDS Rev 2020;22(1):57-58

Infectious Diseases Department, La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
January 2020
3.787 Impact Factor

Factors Related to Hair Antiretroviral Concentration: A Systematic Review of Global Literature.

AIDS Rev 2020 ;22(1):25-33

South Carolina Smart-State Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.

Assessment of antiretroviral (ARV) concentration in hair (hair antiretroviral concentration [HAC]) is one of the latest non-invasive innovations for measuring long-term ARV adherence. We performed a systematic review following Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines to identify the factors that may affect the validity and reliability of HAC. This review included 25 studies that reported data on the associations of hair concentrations of 10 ARVs with 22 potential factors related to HAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000122DOI Listing
January 2020

Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions.

AIDS Rev 2020 ;22(1):44-56

UNIR Health Sciences School and Medical Center, Madrid. Spain.

Human immunodeficiency virus type 2 (HIV-2) was isolated in AIDS patients in 1986. Around 1-2 million people are infected worldwide. The virus is less transmissible than HIV-1, being sexual contacts the most frequent route of acquisition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M20000029DOI Listing
January 2020
3.787 Impact Factor

Do Highly Active Antiretroviral Therapy Drugs in the Management of HIV Patients Influence Success of Dental Implants?

AIDS Rev 2020 ;22(1):3-8

All India Institute of Dental Sciences, Bhubaneshwar, India.

HIV infection is a global pandemic that affects CD4 cells in the immune system and leads to lethal opportunistic infections. The advent of highly active antiretroviral therapy (HAART) has induced a marked reduction in the viral load and an increase in the CD4 cell count, thereby changing the course of the disease from an acute life-threatening condition to chronic disease. Accordingly, need and demand for oral rehabilitation in HIV positive population have increased in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.20000107DOI Listing
January 2020
3.787 Impact Factor

Evolution of Experimental Design and Research Techniques in HIV-1 Reservoir Studies: A Systematic Review.

AIDS Rev 2020 ;22(1):16-24

Department of General Internal Medicine, HIV Cure Research Center, University Hospital Ghent and Ghent University, Ghent, Belgium.

Although HIV-1 has evolved from a deadly to a chronic disease over the past 20 years, an HIV-1 cure is still lacking due to the presence of persisting cellular viral reservoirs which are spread throughout the body in different anatomical compartments. Hence, the identification and characterization of these HIV-1 reservoirs were the focus of many studies during the past decades. In this review, a systematic literature screening and text mining approach were implemented to assess the evolution in experimental design of these HIV-1 reservoir studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M20000028DOI Listing
January 2020

A Global Bibliometric Analysis of Services for Children Affected by HIV/AIDS: Implications for Impact Mitigation Programs (GAPRESEARCH).

AIDS Rev 2020 ;22(1):34-43

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University. Ho Chi Minh City, Vietnam.

Tremendous progress has been made over the past three decades in the fight against the HIV epidemic; however, children experienced substantial physical and psychosocial effects of HIV infection. To inform services and policy development, we analyzed research growth and current trends in studies on children with HIV/AIDS. A total of 17,598 research papers and reviews in English, which were published on Web of Science, were downloaded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000078DOI Listing
January 2020

Why Not an Opioid Epidemic in Europe Like in the USA?

Authors:
Vicente Soriano

AIDS Rev 2019;21(4):234-235

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article

Download full-text PDF

Source

Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection?

AIDS Rev 2019 ;21(4):175-183

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States.

Hepatitis B surface antigen (HBsAg) level plays an important role in conjunction with other markers such as hepatitis B envelope antigen (HBeAg) and hepatitis B virus (HBV) deoxyribonucleic acid levels to predict disease activity in chronic Hepatitis B (CHB). Quantification of HBsAg is useful in differentiating carriers from active hepatitis in HBeAg negative patients, and current guidelines recommend monitoring of pegylated interferon alpha treatment in CHB infection. However, there are only few studies about the role of quantitative HBsAg (qHBsAg) monitoring in HIV-HBV coinfected patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000077DOI Listing

Evolution of Interdisciplinary Landscapes of HIV/AIDS Studies from 1983 to 2017: Results from the Global Analysis for Policy in Research (GAPRESEARCH).

AIDS Rev 2019 ;21(4):184-194

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.

In recent years, there have been numerous calls by researchers to adopt multi-disciplinary and international perspectives to address the HIV pandemic. Meaningful and prudent public health policy should be based on sound empirical data and research. Henceforth, our study aims to contribute to the current literature by conducting a comprehensive global mapping and determine the landscapes of HIV/AIDS research covering the years between 1983 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000083DOI Listing

Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.

AIDS Rev 2019 ;21(4):218-232

Vall d'Hebron Research Institute, Hospital Universitari Vall d'Hebron.

Virus-like particles (VLPs) are a type of subunit vaccine which resembles viruses but do not contain any genetic material so that they are not infectious. VLPs maintain the same antigenic conformation to the original virus, and they could be a better vaccine candidate than live-attenuated and inactivated vaccines. In addition, compared to other subunit vaccines such as soluble protein, VLPs can stimulate both innate and adaptive immune responses effectively and safely against several pathogens by the closer morphology to its native virus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000114DOI Listing

The Role of the Clinical Pharmacist in the Management of People Living with HIV in the Modern Antiretroviral Era.

AIDS Rev 2019 ;21(4):195-210

Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California.

As the HIV epidemic has evolved, so too has the role of the clinical pharmacist (CP) in the management of people living with HIV (PLWH). The modern antiretroviral therapy (ART) era has resulted in PLWH living normal life spans with resulting increased comorbidities. CPs have long been a part of the multidisciplinary management of ART. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000089DOI Listing

HTLV-1 Infection is Rising Up in Spain Whereas HTLV-2 is Vanishing

AIDS Rev 2019 ;21(4):233-235

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article

Download full-text PDF

Source

HTLV-1 Associated Neurological Complex. What is Hidden below the Water?

AIDS Rev 2019 ;21(4):211-217

Institute of Neurology (INDC), Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

The human T-cell lymphotropic virus type 1 (HTLV-1) infects 5-10 million people worldwide and causes fatal and disabling diseases in a significant proportion of them. A chronic myelitis named HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the typical neurological manifestation of HTLV-1. However, other neurological syndromes can be either associated with HAM/TSP or occur in isolation in the HTLV-1 infected individual. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000108DOI Listing

Evolution of Interdisciplinary Landscapes of HIV/Acquired Immune Deficiency Syndromes Studies from 1983 to 2017: Results from the Global Analysis for Policy in Research (GAPRESEARCH).

AIDS Rev 2019 10 3;21(3). Epub 2019 Oct 3.

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University. Ho Chi Minh City, Vietnam

Introduction: In recent years, there have been numerous calls by researchers to adopt multi-disciplinary and international perspectives to address the human immunodeficiency virus (HIV) pandemic. Meaningful and prudent public health policy should be based on sound empirical data and research. Henceforth, our study aims to contribute to the current literature by conducting a comprehensive global mapping and determine the landscapes of HIV/acquired immune deficiency syndromes (AIDS) research covering the years between 1983 and 2017. Read More

View Article

Download full-text PDF

Source
October 2019
3.787 Impact Factor

A Global Bibliometric Analysis of Services for Children Affected by HIV/Acquired Immune Deficiency Syndrome: Implications for Impact Mitigation Programs (GAPRESEARCH).

AIDS Rev 2019 Oct 3;21(3). Epub 2019 Oct 3.

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University. Ho Chi Minh City, Vietnam.

Tremendous progress has been made over the past three decades in the fight against the human immunodeficiency virus (HIV) epidemic; however, children experienced substantial physical and psychosocial effects of HIV infection. To inform services and policy development, we analyzed research growth and current trends in studies on children with HIV/acquired immune deficiency syndrome (AIDS). A total of 17,598 research papers and reviews in English, which were published on Web of Science, were downloaded. Read More

View Article

Download full-text PDF

Source
October 2019
3.787 Impact Factor

Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection?

AIDS Rev 2019 Oct 3;21(3). Epub 2019 Oct 3.

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine. Baltimore, Maryland, United States.

Hepatitis B surface antigen (HBsAg) level plays an important role in conjunction with other markers such as hepatitis B envelope antigen (HBeAg) and hepatitis B virus (HBV) deoxyribonucleic acid levels to predict disease activity in chronic Hepatitis B (CHB). Quantification of HBsAg is useful in differentiating carriers from active hepatitis in HBeAg negative patients, and current guidelines ecommend monitoring of pegylated interferon alpha treatment in CHB infection. However, there are only few studies about the role of quantitative HBsAg (qHBsAg) monitoring in HIV-HBV coinfected patients. Read More

View Article

Download full-text PDF

Source
October 2019
3 Reads

UNAIDS Update Global HIV Numbers

AIDS Rev 2019 ;21(3):170-171

Internal Medicine Laboratory Puerta de Hierro Research Institute and University Hospital Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
January 2020

Viral Inhibitory Activity of CD8+ T Cells in HIV Infection.

AIDS Rev 2019 ;21(3):115-125

Departments of Clinical and Biomedical Sciences, Institute of Tropical Medicine. Antwerp, Belgium.

Cytotoxic T lymphocytes, or CD8+ T cells, play an important role in the control of replication of HIV. Inducing effective and durable HIV-specific CD8+ T cell responses are, therefore, a major objective in prophylactic and curative strategies for HIV infection. To evaluate such strategies, reliable immunological assays are needed that measure the capacity of CD8+ T cells to exert their effector functions and control viremia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000068DOI Listing
January 2020
1 Read

Is Antiretroviral Two-Drug Regimen the New Standard for HIV Treatment in Naive Patients?

AIDS Rev 2019 ;21(3):143-156

Department of Internal Medicine and Infectious Diseases, Acquired Immune Deficiency Syndrome Reference Centre, Cliniques Universitaires Saint Luc, Université Catholique de Louvain. Bruxelles, Belgium.

The use of a combination antiretroviral therapy (cART) has changed dramatically the prognosis and the life expectancy of people living with HIV. The current treatment guidelines continue the convention of preferred cART based on combining a dual nucleoside reverse-transcriptase inhibitor (NRTI) backbone with a third "anchor" agent, such as a ritonavir (r)- or cobicistat (c)-boosted protease inhibitor (PI), a non-NRTI (NNRTI), or an integrase inhibitor (INI) boosted or unboosted. However, due to toxicities of NRTIs, sparing NRTI regimen has been studied for a long time with moderate success due to low efficacy (especially in patients with high viral load and low CD4) compare to standard triple therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000061DOI Listing
January 2020

Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.

AIDS Rev 2019 ;21(3):126-134

Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen. Essen, Germany.

Persistent coinfection with the hepatitis B/D viruses (HDV) represents the most severe form of viral hepatitis. Hepatitis D often leads to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000080DOI Listing
January 2020
4 Reads

"Moving Fourth": A Vision Toward Achieving Healthy Living with HIV Beyond Viral Suppression.

AIDS Rev 2019 ;21(3):135-142

AIDES-France. Pantin, France.

Since HIV has evolved from being a fatal illness to a chronic condition, this brings new challenges relating to long-term health, as increasing numbers of people living with HIV (PLHIV) navigate their lives beyond viral suppression. This review presents the challenges facing patients and health-care providers managing HIV in Europe today. We highlight the challenges that the evolving landscape in HIV brings, including managing an aging and more diverse population of PLHIV; this requires a shift from managing disease to managing health and may best be achieved by multidisciplinary teams in the long term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000088DOI Listing
January 2020

[Conceptual Framework for Investigating and Influencing Adherence Behavior among HIV-Positive Populations: An Applied Social Cognition Model].

AIDS Rev 2019 08 6;21(3):23-27. Epub 2019 Aug 6.

Department of Public Health, Federal Medical Centre, Yola. Adamawa State, Nigeria.

Non-adherence remains a significant barrier to achieving successful HIV treatment outcomes. This review aimed to holistically examine the concept of adherence in the light of current research evidence and to provide a basic and adaptable conceptual framework for investigating and influencing adherence behavior among various HIV populations. We reviewed published journal articles and gray literature within the period from 2000 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000028DOI Listing
August 2019
2 Reads

The Use of Health Behavioral Theories in HIV/AIDS Research: A Bibliometric Analysis (Gap Research).

AIDS Rev 2019 ;21(2):93-107

Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.

With emerging contextual factors and epidemiological transition of HIV/AIDS, the role and contributions of health behavior theories (HBT) are a compelling question after three decades of efforts to eradicate HIV. This study aims at exploring the global and historical evolution of literature and suggesting the most frequent research topics and research gaps in relation to the use of HBT in HIV/AIDS. A cross-sectional analysis of global HIV/AIDS bibliography was conducted through Web of Science (WoS) up to December 31, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000062DOI Listing
November 2019

The Source of New HIV Infections are People not being Treated or Unaware of their Status

Authors:
Vicente Soriano

AIDS Rev 2019 ;21(2):108-109

UNIR Health Sciences School and Medical Center, Madrid, Spain.

View Article

Download full-text PDF

Source
November 2019

Prospects of CRISPR/Cas9 for HIV Elimination

Authors:
Eduardo Seclen

AIDS Rev 2019 ;21(2):109-111

Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, USA.

View Article

Download full-text PDF

Source
November 2019
6 Reads

Differential Contribution of HIV-1 Subtypes B and C to Neurological Disorders: Mechanisms and Possible Treatments.

AIDS Rev 2019 ;21(2):76-83

Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

With the introduction of combinatory antiretroviral therapy, patients infected with human immunodeficiency virus type 1 (HIV-1) can live much longer than before. However, the identification of HIV-associated neurocognitive disorder (HAND), especially HIV-associated dementia in 15-20% of patients infected with HIV-1, indicates additional complexity. These disorders turn out to be subtype dependent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219600PMC
November 2019
4 Reads

The Safety and Efficacy of Marijuana in Persons Living with HIV.

AIDS Rev 2019 ;21(2):84-92

Department of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

The prevalence of the use of marijuana throughout the world is substantial. In light of ongoing increases in accessibility to marijuana, safety and efficacy must be established to guide recommendations for safe use. Of particular interest is at-risk populations such as persons living with HIV (PLWH) in whom there are higher rates of marijuana use and inherent risks of comorbid conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000060DOI Listing
November 2019

Malignant Melanoma in People Living with HIV/AIDS: Can We Know More, Can We Do Better?

AIDS Rev 2019 ;21(2):65-75

Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, Torino, Italy.

Thanks to the advancement in understanding of molecular mechanisms driving immune surveillance, we have now approached a revolutionary era for the treatment of malignant melanoma (MM). Meanwhile, people living with HIV/AIDS (PLWHA) are aging and non-AIDS-related cancers have become a leading cause of death. Both HIV infection and melanoma share common immune-pathological pathways: immune checkpoints are being targeted for melanoma immunotherapy and investigated as a "shock and kill" strategy for latency reversion among HIV-positive individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000038DOI Listing
November 2019
2 Reads

Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis.

AIDS Rev 2019 ;21(2):55-64

Infectious Disease Service, Consorcio Hospital General Universitario de Valencia. Valencia, Spain.

Roughly, 38 million people are living with HIV worldwide. Despite the success of antiretroviral therapy (ART) for suppressing virus replication and restore immunity in infected persons, the HIV epidemics are not controlled globally. Each year 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M19000027DOI Listing
November 2019
1 Read

Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic

AIDS Rev 2019 ;21(1):40-49

Gestione Ambulatoriale Politerapie Outpatient Clinic. ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.

HIV-positive patients are treated with various antiretroviral-containing drug combinations to control their underlying disease, which may also be combined with drugs aimed to manage independent or secondary comorbidities. This can expose patients to drug-drug interactions (DDIs) that may lead to suboptimal drug exposure, an increased risk of therapeutic failure or poor tolerability, and a need to adopt alternative therapeutic strategies. Although such undesired responses to pharmacological therapies can be appropriately managed in some situations, the fact that the available information is usually incomplete which makes it difficult (if not impossible) to assess DDIs and the consequent adjustments of polytherapies in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000035DOI Listing
July 2019
3 Reads

Sexually Transmitted Infections in Men having Sex with Men - Rising Numbers and Wider Etiologies

Authors:
Vicente Soriano

AIDS Rev 2019;21(1):50

Vicente Soriano UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
July 2019
2 Reads
3.787 Impact Factor

A Model for Potential B-cell Precursors of Broadly Neutralizing HIV-1 Antibodies Selection and Antibody Affinity Maturation

AIDS Rev 2019 ;21(1):23-27

Department of Experimental Oncology, National Cancer Research Center. Belgrade, Serbia.

The goal of this report was to propose a model, wherein synergy between the B-cell antigen receptor (BCR) and toll-like receptor (TLR) signaling is involved in the selection of the B-cell precursors of HIV-1 broadly neutralizing antibodies (bnAbs) with long heavy chain complementarity determining regions 3, from immature/transitional B cells. The model predicts the involvement of Ab/HIV-1 complexes in a way that Ab from the complex binds both BCRs and HIV-1, while on internalization of HIV-1 TLR ligands such as CpG motifs interacts with TLR9. The result of BCR and TLR9 orchestrated signaling is a formation of somatically mutated memory B cells potential precursors of bnAbs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000028DOI Listing
July 2019
3 Reads

Gene Editing for HIV Cure at the Edge

Authors:
Vicente Soriano

AIDS Rev 2019;21(1):50a-51

UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
July 2019
2 Reads
3.787 Impact Factor

HIV Treatment Adherence - A Shared Burden for Patients, Health-Care Providers, and Other Stakeholders

AIDS Rev 2019 ;21(1):28-39

Department of Public Health, Federal Medical Centre, Yola, Adamawa State, Nigeria.

Successful HIV treatment is contingent on sustained high levels of treatment adherence. Several barriers to optimal adherence have been documented. In this article, we first review the global burden of non-adherence among HIV/AIDS positive individuals on a public health scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000037DOI Listing
July 2019
2 Reads

Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors

AIDS Rev 2019 ;21(1):4-10

Department of Infectious Diseases, University Hospital Germans Trias i Pujol; Fight AIDS Foundation, Badalona, Barcelona, Spain.

Neuropsychiatric adverse events (NPAEs) observed with the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) are usually mild to moderate. The most prevalent symptoms are insomnia and sleep disorders, but the spectrum also includes dizziness, anxiety, depression, headache, paraesthesia, muscle-skeletal pain, poor concentration, and slow thinking. In recent cohort studies involving >6400 patients in different countries, discontinuation rates due to NPAEs were observed in around 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000023DOI Listing
July 2019
23 Reads

HIV-1 and Compromised Adult Neurogenesis: Emerging Evidence for a New Paradigm of HAND Persistence

AIDS Rev 2019 ;21(1):11-22

Department of Pathology and Laboratory Medicine, Philadelphia, Pennsylvania, USA.

The face of the HIV-1/AIDS pandemic has changed significantly thanks to the development of antiretroviral therapy (ART) regimens. Unfortunately, several HIV-associated comorbidities continuously occur in the clinical population, most notably HIV-associated neurocognitive disorders (HAND). While many molecular and cellular mechanisms have been characterized by describing HAND pathology (specifically neuroinflammatory insults and oxidative stress) in the ART era, compromised adult neurogenesis is emerging as a potential new mechanism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.19000003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6911301PMC
July 2019
5 Reads

Hepatitis Delta Could Be More Frequent than Previously Thought.

AIDS Rev 2018;20(4):236

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
9 Reads
3.787 Impact Factor

Hepatitis E Virus, the Uninvited Intruder in Western Kitchens.

Authors:
Pablo Barreiro

AIDS Rev 2018;20(4):237-238

Hospital Carlos III- La Paz Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
2 Reads

New Dual Combination of Dolutegravir-Rilpivirine for Switching to Maintenance Antiretroviral Therapy.

Authors:
Esteban Ribera

AIDS Rev 2018 ;20(4):179-186

Department of Infectious Diseases, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.

Advances in antiretroviral therapy have led to dramatic improvements in survival of HIV-infected persons. However, HIV cure remains elusive and lifelong treatment is needed. Attempts for reducing long-term drug exposure, toxicities, and cost, while maintaining viral suppression, have led to explore whether maintenance strategies with less than triple therapy could be feasible using the newest more potent antiretrovirals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M18000026DOI Listing
May 2019
6 Reads

Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS.

AIDS Rev 2018 ;20(4):187-204

Sexually Transmitted infections Unit, Centro Sanitario Sandoval. Madrid, Spain.

Nearly 1 million people become infected every day with any of the four major curable sexually transmitted infections (STIs), namely trichomoniasis, chlamydia, gonorrhea, and syphilis. Despite huge global incidence, STIs remain as neglected diseases. The success of antiretrovirals for halting progression to AIDS in HIV-infected individuals and for stopping HIV transmission to uninfected contacts, either as pre- or post-exposure -prophylaxis, has to lead to increased risky sexual behaviors through risk compensation. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/resumen.php?id=1448
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.18000034DOI Listing
May 2019
36 Reads

Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed.

AIDS Rev 2018 ;20(4):220-225

Department of Neuroscience, Center for Translational AIDS Research, Philadelphia, USA.

Here, we review the progress that has been made in achieving a cure of HIV-1 infection. To date, this has only occurred in one person after he received allogeneic stem cell transplants from a CCR5 ∆32 homozygous donor in addition to chemotherapy and radiation to treat his acute myelocytic leukemia. The general consensus is that achieving a sustained remission of infection in the absence of antiretroviral therapy will involve a combination of strategies that involve both the targeting of the latent proviral genome and the induction of more effective anti-HIV-1 immune responses. Read More

View Article

Download full-text PDF

Source
http://www.aidsreviews.com/resumen.php?id=1450
Publisher Site
http://dx.doi.org/10.24875/AIDSRev.18000027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810680PMC
May 2019
36 Reads

Should HIV Patients be concerned about Occult Hepatitis B?

AIDS Rev 2018;20(4):238-239

UNIR Health Sciences School and La Paz University Hospital Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
4 Reads
3.787 Impact Factor

Longer Life Expectancy but still Accelerating Aging in HIV Patients under Antiretroviral Therapy.

AIDS Rev 2018;20(4):236a-237

UNIR Health Sciences School Madrid, Spain.

View Article

Download full-text PDF

Source
May 2019
5 Reads
3.787 Impact Factor

Economic Impact of HIV in the Highly Active Antiretroviral Therapy Era - Reflections Looking Forward.

AIDS Rev 2018 ;20(4):226-235

Research Institute for Evaluation and Public Policies (IRAPP); Universitat Internacional de Catalunya, Barcelona, Spain.

The main data on HIV in high-income countries from the standpoint of health economics are updated and discussed. Specifically, issues surrounding the economic impact of HIV are addressed for health care and occupational perspectives. We review the main epidemiological data on the prevalence of disease and foreseeable changes in patterns within the coming years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/AIDSRev.M17000011DOI Listing
May 2019
4 Reads